Tarpeyo: adverse event reports filed with FDA

5,365

reports as suspect product

0% of all reports · about 1,239 a year

1,383

reports, 12 months to June 2026

894 in the 12 months before

19.3%

marked serious by the reporter

77.7% across the class

1.1%

record death among outcomes, as reported

59 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Tarpeyo reports recording the termmedian drug in corticosteroid

1. Product dose omission issuea dose was missed11%590
2. Weight increasedweight gain10.4%559
3. Fatiguetiredness10.4%558
4. Peripheral swellingswelling of the arms or legs9.3%501
5. Blood pressure increaseda raised blood pressure reading8.7%468
6. Muscle spasmsmuscle cramps8%428
7. Headachehead pain7.3%391
8. Off label useused for a purpose or in a way not on the label6.9%372
9. Hypertensionhigh blood pressure6.4%345
10. Prescribed underdose6.1%328
11. Swelling facea swollen face5.7%305
12. Acneacne5.3%287
13. Dizzinesslight-headedness or unsteadiness5%270
14. Nauseafeeling sick5%267
15. Drug ineffectivethe medicine did not work as expected4.6%248
16. Joint swellinga swollen joint4.1%221
17. Insomniadifficulty sleeping3.7%197
18. Vomitingbeing sick3.4%185
19. Diarrhoealoose or frequent stools3.4%180
20. Increased appetite3.3%175
21. Contusiona bruise3.2%173
22. Swellingswelling3.2%170
23. Product residue present3.1%166
24. Abdominal discomfortstomach discomfort3.1%165
25. Abdominal distensiona bloated abdomen3.1%164
26. Astheniaweakness or lack of energy3%163
27. Rashskin rash2.9%155
28. Cushingoid2.9%153
29. Blood glucose increasedraised blood sugar reading2.7%147
30. Dyspnoeashortness of breath2.7%144

Top 30 of 600 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 74 drugs in the corticosteroid class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 808,789 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 100% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 5,365 reports.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the corticosteroid class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Tarpeyo as a suspect or interacting product; reports listing it only as a concomitant medication (192) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.